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ABSTRACT 
Cancer is the modern, most persistent serial killer. Cancer cells intelligently recruit and 
utilize all the biological functions to support their survival, proliferation, and invasion, which 
require altering and reprogramming a lot of the normal signals and pathways. Calcium (Ca2+) is a 
fundamental secondary messenger involved in most of the regular cellular functions, not only the 
survival processes but also, the apoptotic death. Cancer cells exhibit unique expression levels of 
T-type Ca2+ channels (TTCC) that vary according to the tumor type, stage, and the channel 
isoform. The aberrant expression of the TTCC family (Cav3.1, Cav3.2, and Cav3.3) genes in 
cancer cells significantly contribute in the remodeled Ca2+ signaling that mediates many cancer 
cell functions including mitochondrial energy production, proliferation, angiogenesis, metastasis, 
and sensitivity to cell death. Accordingly, the TTCC blockers were proposed for their anti-cancer 
effect. Mibefradil (MBF) (Posicor®) is a TTCC blocker initially introduced into the 
pharmaceutical market in 1997 as an FDA-approved antihypertensive drug but voluntarily 
withdrawn due to drug-drug interactions. 10 years later, MBF was qualified for drug orphan 
designation by the FDA for the treatment of pancreatic, ovary, and brain cancers. Herein, we 
investigate the anti-cancer effect of MBF on different cell lines by determining its IC50 and 
indicate MBF-induced endoplasmic reticulum Ca2+ release as a key for the anticancer effect of 
MBF. Moreover, we identify the effect of MBF on important cytoplasmic organelles such as 
mitochondria and lipid droplets (LDs). Further, we demonstrate that MBF reduces the number of 
the lipid droplets and affects the cellular lipid storage by inducing lipolysis in cancer cells. 
 
 
 
 
 
INDEX WORDS: Cancer cell, T-type Ca2+ channels, Mibefradil, Thapsigargin, Lipid droplets, 
Lipolysis.  
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1- INTRODUCTION  
 
Calcium (Ca2+) is a ubiquitous and highly dynamic signaling molecule that controls a 
wide range of cellular functions. The momentarily intracellular Ca2+ concentration differs 
according to the ‘on’ reactions responsible for Ca2+ influx to the cytoplasm and the ‘off’ 
reactions causing Ca2+ removal. During the ‘on' reactions, a small amount of Ca2+ binds the 
effectors, which stimulates several Ca2+ dependent processes (Barrige et al., 2003; Monteith et 
al., 2012). 
The Ca2+ signaling is highly versatile and functionally compartmentalized according to 
the spatial and temporal parameters. The on/off Ca2+ dependent reactions are highly involved in 
most of the cellular survival mechanisms and programmed cell death. Therefore, Ca2+ 
homeostasis is a fundamental requirement for the cell survival that is achieved by the continuous 
flow of Ca2+ fluxes and correspondingly balanced and matched during the off and on reactions 
(Barrige et al., 2003; Monteith et al., 2012). 
T-type Ca2+ channels (TTCC) are low-voltage-activated (LVA) Ca2+ channels that start 
opening when the cell is depolarized between -60 and -40 mV. Therefore, TTCC need more 
negative potential than other voltage-gated Ca2+ channels. They are inactivated rapidly after 
opening but close much slower than other voltage-gated Ca2+ channels. For this reason, they are 
termed slowly deactivating T-type channels (Ertel and Ertel, 1997). 
Tumorigenesis is associated with several mutations that exclusively establish the cancer-
specific characters, including self-dependent growth signals, and apoptosis evasion. Thus, some 
cancer cells exhibit deregulated or remodeled Ca2+ signaling pathways that are essential for 
sustaining the phenotypic transformation (Roderick and Cook, 2008). 
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Further, the altered Ca2+ signaling system (Ca2+ toolkit) contributes to cancer progression 
by mediating the proliferation, invasiveness, and acquisition of chemotherapeutic resistance 
(Bergner et al., 2009; Cardenas et al., 2018). Consequently, cancer cells exhibit a variant 
expression of TTCC compared to normal cells, which also differs according to the tumor stage, 
type and channel isoform (Monteith et al., 2012; Sallán et al., 2018)  
As cancer cells undergo uncontrolled proliferation that recruits highly functional cellular 
mechanisms, the Ca2+ influx through the TTCC is essential for performing those functions 
associated with cancer (Büsselberg and Florea, 2017; Monteith et al., 2017). Moreover, the 
relationship of TTCC expression and Ca2+ influx with cancer cell proliferation and apoptosis has 
been presented in different tumors such as glioma (Valerie et al., 2013; Zhang et al., 2012), 
hepatoma (Li et al., 2009), ovarian (Heo et al., 2008; Li et al., 2011), melanoma (Das et al., 
2012), breast (Taylor et al., 2008), leukemia (Toyota et al., 1999), colon (Dziegielewska et al., 
2013), and esophageal cancers (Lu et al., 2008). 
Cav3.2 overexpression is associated with proliferation and hypoxia markers. In addition, 
the Cav3.1 overexpression was associated with BRAFV600E mutation and autophagic activity in 
melanoma cells. Moreover, Cav3.2 transcriptional factors and proteins are excessively expressed 
in some glioblastoma multiforme tumors; similar findings for the Cav3.1 expression were 
reported in Glioblastoma Stem Cells (Maiques Carlos et al., 2018). 
Accordingly, the TTCC was suggested as a target for investigating anticancer effects, 
either by pharmacological inhibition or Cav3.2 gene silencing (Monteith et al., 2012). The 
pharmacological inhibition of TTCC by Mibefradil (MBF) decreased cells proliferation through 
p53-dependent upregulation of CDK inhibitor p21, arresting the G1–S progress in human 
esophageal carcinoma (Lu et al., 2008). Additionally, MBF-induced activation of the p38 
3 
mitogen-activated protein kinase (p38–MAPK) pathway mediated p53 accumulation, causing 
cell-cycle halt and programmed death in colon cancer cells (Dziegielewska et al., 2013). 
In addition, pharmacological blockage of TTCCs or Cav3.2 gene interference inhibited 
the expression of high voltage-activated (HVA) Ca2+ channels and the cAMP-induced 
neuritogenesis in neuroblastoma-glioma cells (NG108-15), which indicates the dual role of 
TTCC at the initial stages of neuronal differentiation, in controlling the morphological changes 
and membrane excitability (Chemin et al., 2002). Additionally, MBF and ascorbic acid (Cav3.2 
inhibitor) diminished the H2S-induced differentiation of NG108-15 cells that involves Src kinase 
phosphorylation (Tarui et al., 2010). 
Moreover, MBF in-vitro treatment of Glioblastoma stem cells suppresses multiple 
oncogenic pathways through downregulation of hypoxia-induced and anti-stress transcriptional 
factors HIF1a and HIF2, inhibits vascular endothelial growth factor (VEGF) expression and 
survivin (apoptosis inhibitor protein). Also, MBF triggered the apoptotic cell death through the 
activation of caspase-9, BAX, PARP, Rb, and p27 in Glioblastoma stem cells (Zhang et al., 
2017). Additionally, MBF was shown to improve ovarian cancer cells sensitivity to carboplatin 
(platinum-based anticancer drug) both in-vitro and in-vivo, by reducing Protein Kinase B 
phosphorylation and down-regulation of survivin expression that abolishes the platinum 
resistance in ovarian cancer (Dziegielewska et al., 2016).  
In-vitro administration of MBF and its structural analog (NNC-55-0396) to leukemia cell 
lines suppresses cell proliferation and growth by down-regulating the ERK signaling pathway 
through intracellular Ca2+ regulation that modulates the activation of p44/42 MAP kinase; also, 
NNC-55-0396 disturbs the intracellular Ca2+ homeostasis, causing Ca2+ efflux from the ER. The 
released Ca2+ affects the mitochondria through mitochondria-associated endoplasmic reticulum 
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(ER) membranes, resulting in mitochondrial depolarization, swelling, and uncoupling (Huang et 
al., 2015).  
Taken together, inhibition of TTCC disrupts the intracellular Ca2+ homeostasis, resulting 
in ER and mitochondrial stress; consequently cells exhibit mitochondrial loss of function and 
apoptotic cell death (Huang et al., 2015). Further, in-vivo studies using an immune-deficient 
xenograft mouse model showed that the application of NNC-55-0396 (MBF analog) suppressed 
ovarian cancer growth (Huang et al., 2004). Moreover, the oral administration of MBF improved 
the efficacy of subsequent administration of temozolomide (alkylating antineoplastic agent used 
for brain cancer treatment) in glioblastoma multiforme tumor burden mice (Stupp et al., 2002). 
Interestingly, cancer cell exhibits abnormal lipid metabolism associated with increased 
lipogenesis. The high rate of lipid production in cancer cells is essential for several biological 
functions, such as energy storage, cellular signaling, and production of phospholipids blocks 
required for proliferation. The cancer microenvironment is characterized by improper oxygen 
supply (hypoxia) and nutrient scarcity. Consequently, cancer cells establish the Warburg effect 
by exhibiting excessive glucose uptake and glycolysis rate, associated with an increase in fatty 
acid synthesis, fatty acid uptake, and lipid content to be stored in LDs. Several studies have 
linked the aggressiveness of tumors with the abundance of LDs. Usually, cancer cells utilize the 
lipid stored in LDs upon need by recruiting the autophagy pathway to include the LD in 
autophagosomes that fuse with a lysosome to form an autolysosome. Hence, the cancer cell 
shows a modified lipolysis mechanism correlated with lipophagy. Moreover, a relation between 
ER-stress and lipophagy in cancer cells has been reported (Maan et al., 2018). 
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Despite the early diagnosis and advanced medical interventions, the number of cancer 
patients is increasing dramatically. In addition to the rate of resistance, recurrence, and collapse 
continuously grow. Further, cancer patients are vulnerable to numerous side effects due to 
radiotherapy and chemotherapy (Carr et al., 2014; Seegenschmiedt, 2004). Therefore, there is an 
urgent need for a comprehensive research to understand the molecular and physiological changes 
of cancer cells to introduce a highly specific anticancer therapy with minimal side effects. 
Herein, this study shows the efficacy of MBF in different cancer cell lines by evaluating 
its IC50.We also identified the MBF-induced ER Ca
2+ release as an essential event for the 
observed effects of MBF.  Moreover, our data indicate a unique effect of MBF on mitochondrial 
membrane potential and cytosolic lipid droplets in cancer cells. 
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2- CHAPTER 1 
THE ANTICANCER ACTION OF MIBEFRADIL 
ON DIFFERENT CANCER CELL LINES 
 
2.1 Introduction: 
The TTCC blockers were proposed to have anticancer effects due to the identified unique 
expression of TTCC in different cancer cells and their essential role in Ca2+ signaling that 
controls most of cancer cells functions (Monteith et al., 2012; Sallán et al., 2018). 
Administration of MBF at a dose of 10 µM into human non-small-cell lung cancer 
(A549) cells showed 66% G1-phase arrest after 24 and 48 h of treatment. (Byun et al., 2016). 
Blocking TTCC with MBF inhibited the growth of the leukemia cell lines, MOLT-4 (T 
lymphoblast) and Jurkat (immortalized T lymphocyte) cells, about 20% to 40% after 48 h 
treatment in doses between 5 to 10 µM respectively. The MBF significantly increased the 
number of cells arrested in the sub-G1 phase, which is an indicator of apoptosis in both cell lines. 
MBF modulated the expression of p44/42 MAP kinase in MOLT-4 cells and decreased the 
phosphorylation of pERK1/2 in a dose-dependent pattern, which suggests that the effect of MBF 
on cytosolic Ca2+ concentration [Ca2+]i might modulate the phosphorylation activation of p44/42 
MAP kinase that accordingly might contribute in inhibiting the cells growth (Huang et al., 2015).  
In Glioblastoma multiforme (GBM) tumor cells, MBF inhibited the cell survival with 
IC50 ~ 5 µM and induced apoptosis. Also, administration of MBF reduced the phosphorylation of 
the mTORC2 subunit and phospho-Akt that are important proteins for tumor sustainability. 
Further, MBF-induced GBM cells apoptosis by increasing caspase-3/7 activity, PARP and DNA-
PK cleavage; those apoptosis associated events have not been shown with the administration of 
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L-type Ca2+ channels (LTCC) blockers. Also, MBF elevated the level of caspase-8 cleavage and 
Bid degradation that contributes to the apoptosis pathway (Valerie et al., 2013). 
In-vivo, oral administration of MBF alone at a dose of 45 mg/kg, four times daily, 
potentially delayed the Glioblastoma multiforme (GBM) tumor growth in a xenograft mouse 
model. Further, combining the previously described dose of MBF with temozolomide at a dose 
of 10 mg/kg/day through intraperitoneal injection, resulted in 100% tumor inhibition after 50 
days of treatment (Keir et al., 2013).  
Administration of MBF to A2780, A2780Cis, and IGROV-1 cells (cisplatin-resistant 
ovarian cancer cell lines) showed dose-dependent growth inhibition with IC50 about 7, 8, 10 µM 
respectively. Further, the MBF treated cells exhibited cell cycle arrest in G1 and G2 phases and a 
reduced number of cells enter S phase, which accompanied with a dose-dependent reduction in 
the expression of p27, cyclin D1, and Rb, and decreased phosphorylation of Rb as well 
(Dziegielewska et al., 2016; Jang et al., 2013; Li et al., 2011).  
Also, the sub-G1 population of ovarian cells was increased after MBF treatment, which 
indicates cell-cycle arrest. Administration of MBF at a dose of 10 µM for 24 h increased the 
expression of prominent apoptosis markers: caspase 9, caspase 7, and cleaved PARP, and 
decreased the expression of the anti-apoptotic factor “survivin”. Further, coadministration of 
MBF with carboplatin overcame the cisplatin resistance of ovarian cancer cells (A2780Cis) and 
increased the cells sensitivity to carboplatin both in-vitro and in-vivo. The in-vivo study was 
performed on nude mice that were intraperitoneally injected with cisplatin-resistant ovarian 
cancer cells (Dziegielewska et al., 2016). 
MBF treatment induced a dose-dependent inhibition in the viability of Glioma-initiating 
cells (GIC) for doses less than 10 mM. Also, MBF was indicated to alter the plasma membrane 
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potential of GIC, thus affecting glucose transport and leading to cell starvation. Also, the effect 
of MBF on the intracellular Ca2+ homeostasis induced ER stress and triggered the unfolded 
protein response of the ER that resulted in cell death via apoptosis (Niklasson et al., 2017). 
Furthermore, treating the Glioblastoma stem-like cells (GSC) with 5 μM of MBF for 5 days 
significantly decreased cell proliferation and induced cell death (Zhang et al., 2017).  
The continuous growth of the tumor mass increases the distance between the tumor cells 
and the blood vessels. Consequently, cancer cells, especially those at the center of the tumor 
mass, suffer from low oxygen tension (hypoxia). Tumor cells overcome the hypoxia associated 
with the tumor mass by overexpressing HIF1α and HIF2α, which act as anti-stressors and 
antiapoptotic factor (Keith et al., 2012). 
Moreover, hypoxic GSCs are shown to overexpress the Cav3.2 coincidently with HIF1α 
and HIF2α overexpression. Treating GSCs with MBF at a dose of 5 μM decreased the HIF1α 
and HIF2α expression that allows the cells to undergo stress-induced apoptosis. Also, MBF in 
the same dose reduced the effect of the mTOR protein that associated with the tumor initiation 
and development, also, resulted in the overexpression of the proapoptotic proteins Bax and p27. 
Additionally, oral treatment of GSC tumor burden mice (tumor cells were injected in corpus 
striatum) with MBF at a dose of 24 mg/kg every 6 hours significantly inhibited tumor growth, 
which was measured using magnetic resonance imaging (MRI) (Zhang et al., 2017). 
In digestive system cancers, MBF was shown to decrease the proliferation of esophageal 
carcinoma cells by overexpression of cyclin-dependent kinase inhibitor (p21Cip1/Waf1) (Lu et 
al., 2008). Moreover, MBF administration into colon cancer cells (HCT-116) induced apoptosis 
due to the overexpression of the tumor suppressor protein (p53), p53 upregulated modulator of 
apoptosis (PUMA), and p21Cip1/Waf1(Dziegielewska et al., 2013). 
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The MTT (3-[4,5-dimethyl-2-thiazolyl]-2, 5-diphenyl-2H-tetrazolium bromide) assay is 
commonly used to measure cellular viability, toxicity, and proliferation (Dziegielewska et al., 
2013; van Meerloo et al., 2011). MTT is water-soluble, can be dissolved in the growth medium, 
and is easily taken up by cells via endocytosis (Liu et al., 1997). The MTT dye is reduced by 
cellular dehydrogenases and reducing agents, especially mitochondrial succinate dehydrogenase, 
into an insoluble formazan dye that can be dissolved using organic solvents such as DMSO. The 
reducing power of the cell mainly depends on reducing of nicotinamide adenine dinucleotide 
coenzyme (NAD), as well as many other intracellular reducing compounds, such as 
dihydrolipoic acid, ascorbic acid, cysteine, glutathione, and tocopherols. Therefore, the MTT 
assay is considered as a comprehensive indicator of mitochondrial activity and cellular viability 
accordingly. Usually, the MTT assay can be used to measure the change in the cellular viability 
after a particular treatment. The amount of produced formazan is directly proportional to the 
number and activity of the cells that can be estimated by measuring the optical density of formed 
formazan crystals after being dissolved in DMSO. The accuracy of the MTT assay comes from 
comparing the amount of the formazan produced from treated cells against untreated cells under 
the same condition (Van den Berg, 2015).  
 
2.2 Materials and Methods: 
2.2.1 MTT Assay for Different Cancer Cell Lines: 
MTT MTT (3-[4,5-Dimethylthiazol-2-Yl]-2,5-Diphenyltetrazolium Bromide) assay was 
performed for detecting the effect of MBF on the viability of various cancer cell lines and for 
estimating the IC50 (half maximal inhibitory concentration) of the MBF for different cancer cell 
lines. The cells were seeded in 96 well plates at a density ≃ 5000 cells per well in 100 µL of 
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suitable medium. Three 96 well plates were inoculated for each cell line (triplicate). The plates 
were incubated for 24 hours (h) in standard conditions (5 % CO2 at 37 
oC), which is required for 
cells to attach. The medium was exchanged with medium containing MBF in the tested wells 
(Number of repeats [N] = 6 wells, columns 4-12, rows A-F). Doxorubicin hydrochloride (an 
FDA approved anticancer drug, Cayman Chemical, MI, USA) was used as the positive control 
(N = 6 wells, columns 4-12, rows G, H), N = 2. All drugs were prepared as dimethyl sulfoxide 
(DMSO) stock solutions. The negative control wells (N = 24 wells, columns 1-3, rows A-H) 
were treated with DMSO. The DMSO final concentration was 1% in all wells. The columns of 
MBF and doxorubicin were treated in two-fold serial dilution (50, 25, 12.5, 6.3, 3.1, 1.6, 0.8, 0.4 
µM) (Figure 1). After 48 h incubation in standard conditions, the medium was removed, and the 
cells were washed with 1x DPBS (Corning®). For each well, 100 µL of (0.5 mg/mL) MTT dye 
(Thiazolyl Blue Tetrazolium Bromide, Sigma-Aldrich®) was added in the appropriate medium. 
After 4 h incubation in standard condition, the medium containing the MTT dye was removed 
and 100 µL DMSO was added for each well, and the plates were incubated in the dark for 30 
minutes in order to dissolve the formazan crystals. The optical densities (ODs) of the contents of 
the wells were measured using a microplate reader (MD SPECTRAmax Plate Reader) at 
wavelength 570 nm. For each MBF and positive control conc, the mean of the percentage 
inhibition was calculated using the following equation: 
Average OD of the treated wells
Average OD of the control wells (N=24)
 × 100. 
Also, the logarithm of the treatment concentration (Log) and the standard deviation (SD) 
were calculated using Microsoft Excel. To estimate the IC50, the % inhibition versus Log 
concentration was analyzed using the GraphPad Prism 6 (GraphPad Software, CA, USA) for 
nonlinear regression analysis. 
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2.2.2 Statistical Analysis: 
GraphPad Prism 6 software was used for data plotting, graphing, and statistical analysis. 
The results were calculated by Microsoft Excel to obtain the log concentration of the drugs, the 
percentage viability of the cells in each well and standard deviation (SD). The curves were fitted 
using GraphPad nonlinear regression by blotting the log concentration of the drug versus the 
average viability, SD, and N (number of repeats). The data were analyzed by GraphPad as 
inhibitor versus response (variable slope) to conclude the IC50. 
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Figure 1 The treatment design of the MTT assay. 
 
Figure 1: MTT assay for in-vitro detection of the anticancer effect of MBF on various 
cancer cell lines in 96 well plates. The effect of MBF was estimated against negative control 
cells treated with DMSO in equal conc. Also, the MBF IC50 was compared with the positive 
control rows that were treated with doxorubicin. 
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2.3 Results: 
2.3.1 The Effect of MBF on the Viability of Various Cancer Cell Lines: 
In-vitro administration of MBF to various cancer cell lines in both 24 and 48 h assays 
reduced the cells’ viability and showed markedly low IC50 values that are relatively close to the 
IC50 values of the positive control drug doxorubicin hydrochloride. The MTT assay was used for 
determining the cells’ viability after treatment with MBF and doxorubicin in different doses (50, 
25, 12.5, 6.3, 3.1, 1.6, 0.8, 0.4 µM). Treating the triple negative breast cancer cells (TNBC) 
(MDA-MB-231, MDA-MB-468, and HCC-1806), Pancreatic cancer cells (CFPAC-1, Panc-1, 
and Panc-89), and Prostate cancer cells (DU-145) with MBF significantly affected the cells’ 
viability in a dose dependent manner. Cell survival was decreased by increasing the MBF 
concentration over 1 μM (Figure 2, A-G). The non-linear regression analysis of the 48-h MTT 
assay showed IC50 values of MBF ranging from 4 - 11 μM (Table 1, A). The 24-h treatment of 
TNBC (MDA-MB-231 Luciferase) and prostate cancer cells (PC-3 Luciferase) showed higher 
IC50 values, 23 and 24 μM respectively (Figure 2, H, I) (Table 1, B). In both assays, treating the 
cells with MBF concentrations smaller than 1 μM did not have an effect on cell viability after 24 
h and 48 h of treatment. 
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❖ Red points on the graphs represent the outliers. 
Figure 2 Nonlinear regression analysis of MTT results using GraphPad Prism 6. 
 
Figure 2: The non-linear regression analysis of the MTT assay results using 
GraphPad Prism 6 indicates a sigmoid relation between the log MBF concentration and the 
cells’ viability. (A-G) Treating various cancer cells with MBF for 48 h resulted in dose-
dependent inhibition. MBF concentration higher than 20 μM caused more than 80% 
inhibition in viability, while 1 μM and less did not impact the viability. (H-I) The 24-h assay 
also showed sigmoid relation, but the effective concentration was almost double that of the 
48-hour assay. 
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Table 1: The MBF IC50 doses for different cancer cell lines were calculated using the 
GraphPad nonlinear regression analysis of the sigmoid relation between the Log of MBF 
concentration and the % viability (A) The 48-h MTT assay of different cancer cell lines indicated 
the MBF IC50 from 4 to 11 μM, while doxorubicin, which is effective only on breast and prostate 
cancer cells, showed an IC50 was between 3 – 1 μM. (B) The 24-h MTT assay of two cell lines 
showed higher IC50 than 48-h assay.  
 
Table 1 The MBF IC50 doses for different cancer cell lines. 
(A)                             Cell Line MBF IC50 Doxorubicin IC50 
MDA-MB-468 (TNBC cells*) 4 µM 2 µM 
MDA-MB-231 (TNBC cells) 9 µM 3 µM 
HCC-1806 (TNBC cells) 8 µM 1 µM 
DU-145 (Prostate cancer cells) 7 µM 1 µM 
CFPAC-1 (Pancreatic adenocarcinoma cells) 6 µM - 
PANC-1 (Pancreatic cancer cells) 11 µM - 
PANC-89 (Pancreatic cancer cells) 5 µM - 
 
(B)                     Cell Line MBF IC50  
PC-3 Luc (Prostate cancer cells) ≃ 23 µM 
MDA-MB-231 Luc (TNBC cells) ≃ 24 µM 
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2.4 Discussion: 
Recently, there were many studies that investigated the anticancer effect of MBF on 
specific cell lines, especially on glioma cells. Therefore, identifying the anticancer effect of MBF 
on variant cancer cell lines and detecting its IC50 for those different cells confirms the inhibitory 
action of MBF on cancer cells and can suggest that MBF targets a common pathway in cancer 
cells. Since TNBC and pancreatic cancer cells cause serious and life-threatening illnesses, this 
study paid more attention to investigating the effect of MBF on both cancer cell lines spatially 
HCC-1806 and CFPAC-1 cells respectively. 
Initially, the MTT assay was performed for identifying the effect of MBF on the activity 
and viability of different cancer cells. Because the MTT dye is reduced by the mitochondrial 
dehydrogenases (Van den Berg, 2015), the MTT assay measures the mitochondrial enzymatic 
capacity as is a useful indicator of cell viability. Without intact mitochondria, cells cannot 
survive or divide, and mostly undergo apoptosis. While the amount of produced formazan is 
dependent on overall mitochondrial activity, it is reflective of mitochondrial function, but also on 
the number of cells. 
Administration of MBF to different cell lines resulted in significant inhibition of cell 
survival in comparison to the DMSO-treated control cells (Figure 3). The MBF IC50 values were 
between 4-11 µM. MBF in doses equal to or less than 1 µM had no effect on cell viability in 
either of the cell lines. The cells treated with doxorubicin as a positive control exhibited IC50 
values between 1-3 µM. Thus, MBF inhibited the cancer cells with an IC50 relatively similar to 
that of doxorubicin, an FDA approved anticancer chemotherapy drug (Table 1). 
Because the MTT assay was carried out over 48 h, the cells had time to perform one or 
two cycles of cell division. Therefore, while the MTT results are an indicator of mitochondrial 
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function, changes in formazan concentration can result from mitochondrial dysfunction leading 
to cell death and apoptosis, effects on proliferation, or both, as fewer cells consequently will 
produce less formazan dye. The overall results indicate that MBF has an inhibitory effect on cell 
survival and/or proliferation. Therefore, the effect of MBF on cell death either apoptosis or 
necrosis can be determined by AnnexinV/PI apoptosis assay. 
The inhibitory effect of MBF on TTCC and other ion channels was at the heart of 
multiple studies over the last 20 years (Sallán et al., 2018; Strobeck et al., 1999). The reported 
IC50 dose of MBF for inhibition of? TTCC was 0.14 – 0.27 µM (Perez-Reyes, 2003). Given our 
findings that the IC50 dose of MBF for different cancer cells was more than 40 times the required 
concentration for blocking the TTCC, and at least 6 times the concentration required for 
inhibiting voltage-gated Na+ channels and volume-activated Cl- channels, we conclude that MBF 
causes cancer cell death by a mechanism other that the proposed inhibition of TTCC. 
 
2.5 Conclusion: 
MBF exhibited a potent inhibitory effect on the viability of different cancer cells. MBF 
inhibited cancer cells in a dose-dependent manner. It had no effect at concentrations less than 1 
µM and showed complete inhibition at concentrations higher than 25 µM. The IC50 values of 
MBF for different cancer cell lines ranged from 4-11 µM, which is more than 40 times the IC50 
dose for blocking TTCC. 
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3- CHAPTER 2 
REGULATION OF INTRACELLULAR CALCIUM SIGNALING BY MIBEFRADIL 
 
3.1 Introduction: 
Calcium ions (Ca2+) play a fundamental role in the cellular biological functions. Usually, 
Ca2+ signaling takes place upon increasing the intracellular Ca2+ concentration in cells (Berridge, 
1997). The temporal and spatial change of [Ca2+]i act as “on” and “off” signals allowing the cell 
to depend on Ca2+ as a secondary messenger.  
The extracellular Ca2+ concentration is about 10,000-fold higher than the 
intracellular concentration. Therefore, the plasma membrane contains various types of Ca2+ 
channels that regulate Ca2+ influx into the cell so that Ca2+ can perform specific signaling 
functions. For switching the Ca2+ signal into “off” mode, the cell quickly gets rid of the excess 
cytosolic Ca2+ by recruiting Ca2+ATPases in the plasma and ER membranes, and exchangers in 
the plasma membrane that exploit the concentration gradient of some other ions such as Na+. The 
ER is the principal store of Ca2+ inside the cell and it maintains about 103 to ~104 times the 
[Ca2+]i (Samtleben et al., 2013).  
The Ca2+ is released from the ER upon specific signals, such as inositol 
trisphosphate (IP3), and restored by specific Ca
2+ATPases called SERCA 
(Sarcoplasmic/endoplasmic reticulum Ca2+ATPase) that can be blocked by Thapsigargin (Thap) 
(Lytton et al., 1991).  
Also, mitochondria have an important role in regulating the [Ca2+]i by operating a Ca
2+ 
uniporter that has low affinity but a high capacity for taking the cytosolic Ca2+ into the 
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mitochondria. Some of the cytosolic Ca2+ removal mechanisms can contribute to a cytoplasmic 
increase in Ca2+ concentration (e.g., reverse-mode Na+/ Ca2+ exchange and Ca2+ATPases). In 
addition, mitochondria can elevate [Ca2+]i by increasing its membrane permeability and releasing 
Ca2+ into the cytosol (Berridge et al., 2000; Ichas et al., 1997; Lipp and Niggli, 1994; Montero et 
al., 2000). 
Many important cellular functions are mediated by Ca2+ signaling, including cell 
contraction, crosstalk, membrane excitability, secretion, metabolism, vesicle trafficking, 
proliferation, and cancer cell proliferation and metastasis, in addition to roles in mitochondria 
that involve ATP production and apoptosis (Berridge et al., 2000). In cancer cells, altered Ca2+ 
signaling and increased Ca2+ influx were found to contribute to tumor progression by promoting 
proliferation, enhancing invasiveness, and granting chemotherapeutic resistance (Büsselberg and 
Florea, 2017; Monteith et al., 2017). 
In the carcinogenesis process, cells undergo multiple mutations that trigger an abnormal 
and uncontrolled division, which requires an increase in metabolic demand, resistance to cellular 
stress and suppression of apoptosis. Most of the biological functions related to cancer formation 
and progress depend on Ca2+ signaling. Therefore, cancer cell shows more frequent Ca2+ 
signaling and overexpression of Ca2+ channels including TTCC. Also, cancer cells depend on a 
highly active ER and conduct de novo lipogenesis at a high rate (Monteith et al., 2007; Roderick 
and Cook, 2008; Sallán et al., 2018). 
The benzimidazolyl-substituted tetraline derivative MBF is a Ca2+ channel blocker that 
inhibits L-type Ca2+ channels in the cardiovascular system (Clozel et al., 1997), while in the 
arterial and vascular myocytes, it preferentially blocks T-type Ca2+ channels (Bezprozvanny and 
Tsien, 1995; Clozel et al., 1997; Vortherms et al., 2011). MBF was found to inhibit TTCC and 
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LTCC, with higher affinity of about 10 to 15-fold for TTCC over LTCC. The reported IC50 for 
TTCC and LTCC channels was ~1 and ~50 nM, respectively (Martin et al., 2000).  
Interestingly, MBF was also shown to block voltage-gated Na+ channels with an IC50 
dose ~ 1 µM (Eller et al., 2000; McNulty and Hanck, 2004). In addition, MBF was found to 
block N-type calcium channels (high voltage activated channels) at an IC50 dose of 7.51 µM 
(Vortherms et al., 2011). Another study identified that the inhibitory effect of MBF on voltage-
gated Na+ channels depended on the state of the channel (state-dependent), meaning that MBF 
had a preferential affinity to certain channel conditions over others; for example, the blocking 
effect of MBF on Nav1.5 was greater when the cell was held at -100 mV than at -130 mV 
(McNulty and Hanck, 2004). 
Moreover, MBF showed an inhibitory effect on volume-activated Cl- channels with a 
Ki=5.4±0.22 µM (Nilius et al., 1997). The highest reported MBF IC50 dose that blocks cloned 
TTCC was 0.14 – 0.27 µM; this experiment was conducted in ~ 2 mM Ca2+ (Perez-Reyes, 2003). 
Mitochondria-associated ER membranes are the normal connection between the 
mitochondria and ER and are rich in enzymes, channels including Ca2+ channels, and proteins 
including those with oncogenic/oncosuppressive functions. Cancer cells exhibit an alteration in 
the Mitochondria-associated ER membranes function and activity such as increasing the ER-
Mitochondria interface in breast cancer cells through Sig1R (stress-activated chaperone sigma-1 
receptor) overexpression and decreasing the Ca2+ current through the ER-Mitochondria interface 
for reducing the apoptosis (Morciano et al., 2018).  
Treating Jurkat cells (immortalized human T cells) with topoisomerase inhibitor 
“camptothecin” caused mitochondria membrane hyperpolarization, resulting in releasing of 
cytochrome c. Releasing of cytochrome c from the inner membrane of mitochondrion to the 
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cytoplasm activated caspases that are protease enzymes triggering programmed cell death 
“apoptosis”.(Sanchez-Alcazar et al., 2000). 
Using the fluorescent Ca2+ indicator, Fura-2 AM (Fura-2-acetoxymethyl ester), is a very 
common and efficient means to detect and quantify changes in the cytosolic [Ca2+]i. After 
loading cells with Fura-2 AM, the acetoxymethyl ester is cleaved by the cellular esterases and 
allows the Fura-2 to bind cytosolic Ca2+. The emission intensity and the spectrum shift of the 
Fura-2 differ according to the amount of bound Ca2+. After excitation at 340 and 380nm, the 
emission is collected at 510 nm. Appling ratiometric analysis for the collected emission at 340 
and 380 potentially improves the sensitivity of the Ca2+ imaging and overcomes the loading 
errors and background noise (Chen et al., 2006; Vortherms et al., 2011).  
The mitochondrial membrane potential (MX) is a potential indicator of mitochondria 
soundness and its membrane integrity; MX deviations are a strong indicator of apoptosis. 
Tetramethylrhodamine ethyl ester (TMRE) is a permeable fluorescent dye that reversibly binds 
the negatively charged mitochondrial membrane. Measuring the emission intensity of the bound 
TMRE in mitochondrial membranes versus the background is used to determine MX. Upon a 
change in the MX, the TMRE dissociates from or associates back into the mitochondrial 
membrane, resulting in an overall change in TMRE fluorescence. TMRE is excited at 548 nm, 
and the emission is collected at 575 nm (Bernas and Dobrucki, 2002; Farkas et al., 1989; 
O’Reilly et al., 2003). 
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3.2 Materials and Methods: 
3.2.1 Fura-2 Calcium Imaging: 
The cells were cultured in 35 mm plates at a seeding density of 0.3 x 106 in 2 mL of 
medium. After 24 h incubation in standard condition, the media was removed, and new 2 mL of 
loading medium containing Fura-2 AM (Fura-2-acetoxymethyl ester, Molecular Probes®, 
Eugene, OR, USA) at concentration of 5 µM and 0.02 % Pluronic F-127 (Invitrogen®, Thermo 
Fisher Scientific) was added. The cells were incubated for 45 minutes in standard condition for 
loading the Fura-2 AM into the cells. After incubation, the cells were washed with an 
extracellular solution (ECS) 3 times, then 4 mL of ECS was added to the plate. The plate was 
kept in the dark at room temperature for 45 minutes for cleaving the acetoxymethyl groups of the 
Fura-2 AM by cellular esterases.  
Time-lapse Ca2+ imaging was performed using an Olympus IX70 inverted microscope 
equipped with phase contrast optics and a cooled CCD camera. Fura-2 was excited at 340 and 
380 nm (8% intensity), and the emission was collected at 510 nm at each excitation wavelength. 
The emission intensities obtained at excitation wavelength of 340 and 380nm were ratioed to 
determine the [Ca2+]i. The cells were imaged for 4 minutes to obtain a baseline of [Ca
2+]i, upon 
which the treatment was added and cells imaged for an additional ~40 minutes. The regions of 
interest (ROIs) were adjusted such that at least 5 cells were imaged simultaneously, and the assay 
was at least repeated twice. 
 
3.2.2 Mitochondrial Membrane Potential Assay: 
The cells were cultured in 35 mm plates at a seeding density of 0.3 x 106 in 2 mL of 
medium. After 24 h incubation in standard condition, the media was removed, and new 2 mL of 
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loading medium containing 200 nM of TMRE (Molecular Probs®, Eugene, OR, USA) was 
added. The cells were incubated for 30 minutes in standard condition for loading the TMRE into 
the cells. After incubation, the cells were washed with ECS 3 times, then 4 mL of ECS was 
added to the plate. The plate was kept in the dark at room temperature for 15 minutes for 
stabilizing the TMRE bound into the mitochondrial membrane. Time-lapse TMRE imaging was 
performed using an Olympus IX70 inverted microscope equipped with phase contrast optics and 
a cooled CCD camera. TMRE was excited at 548 nm (6-8 % intensity), and the emission was 
collected at wavelength 575. TMRE emission was analyzed ratiometrically against the 
background to determine the mitochondrial membrane potential (MX). The cells were imaged 
for 4 minutes to obtain a stable baseline reading for the MX, after which the treatment was 
added, and cells were imaged for an additional ~40 minutes. 
 
3.2.3 Statistical Analysis: 
GraphPad Prism 6 software was used for data plotting, graphing, and statistical analysis. 
The graphs showed the points representing the average response versus time and the connecting 
line. Results are expressed as mean±SE (standard error). The results were calculated using 
Microsoft excel to obtain the percentage of change. The percentage of change was plotted using 
GraphPad Prism 6 column analysis and expressed as mean±SE. 
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3.3 Results: 
3.3.1 The Effect of MBF on Cytosolic Calcium Concentration [Ca2+]i: 
Initially, the effect of DMSO on the [Ca2+]i was measured using the Fura 2 calcium 
imaging, because all the drugs used were dissolved in DMSO. Treating the cells with DMSO 
equal to the concentration used for dissolving the drugs did not change the intracellular [Ca2+]i  
as indicated by the constant 340/380 fluorescence ratio of Fura-2 AM before and after adding of 
DMSO (Figure 3, A). Treating CFPAC-1 cells with MBF at a dose equal to the IC50 (6 μM) 
caused ~ 350% increase in the [Ca2+]i in comparison to the baseline obtained before adding the 
MBF (Figure 3, B; Figure 5). Also, treating HCC-1806 cells with 8 μM of MBF (equal to IC50) 
resulted in ~ 110% increase in the [Ca2+]i (Figure 3, C; Figure 5). Interestingly, MBF 
administration at a dose of 0.98 μM into CFPAC-1 cells did not increase the [Ca2+]i  (Figure 3, 
D). 
 
3.3.2 Determine the Mechanism of Increasing the Cytosolic Ca2+ Concentration by 
MBF: 
To determine if the increase in [Ca2+]i resulted from Ca
2+ influx across the plasma 
membrane from the extracellular medium, Fura-2 calcium imaging of CFPAC-1 cells was 
repeated in calcium-free ECS to eliminate the calcium gradient across the plasma membrane. 
Administration of MBF at a dose of 6 μM in calcium-free ECS still resulted in ~ 100% increase 
in the [Ca2+]i (Figure 4, A), suggesting that some of the increase in [Ca
2+]i seen in response to 
MBF above was not caused by Ca2+ influx, but instead was likely due to release from 
intracellular stores. To test whether the ER might be a source of Ca2+ release, MBF treatment 
was next repeated on cells in which the ER had been previously emptied, with the rationale that 
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MBF should no longer be able to trigger a Ca2+ release from the ER. Therefore, CFPAC-1 cells, 
in normal Ca2+ containing ECS, were pretreated with the SERCA pump inhibitor Thap for 13 
minutes, followed by the application of MBF. Pre-administration of Thap at a concentration of 
10 μM to CFPAC-1 cells fully blocked the effect of MBF on increasing the [Ca2+]i suggesting 
that the Ca2+ increase elicited by MBF treatment was via release from the ER (Figure 4, B). 
Interestingly, Thap administration by itself transiently increased the [Ca2+]i. Taken together the 
administration of MBF at a dose equal to the IC50 caused more than 100% increase of [Ca
2+]i in 
both HCC-1806 cells and CFPAC-1 cells, even in calcium-free ECS, whereas Thap blocked the 
[Ca2+]i increase induced by MBF (Figure 5). The peak of [Ca
2+]i increase was ~ 350% in 
CFPAC-1 cells and ~ 110% in HCC-1806 cells that treated with MBF in normal Ca2+ containing 
ECS, whereas it was ~ 100% in CFPAC-1 cells that treated with MBF in Ca2+ free ECS. Those 
variations in the peak might be due to the natural differences between the cells that originated 
from pancreatic cancer (CFPAC-1) and breast cancer (HCC-1806). In addition to the CFPAC-1 
cells contain mutant cystic fibrosis (CF) gene that modifies the structure of the ER (Antigny et 
al., 2011; Schoumacher et al., 1990). Moreover, the differences between the cells age and the 
temporal functions when the assay was being conducted might affect the amount of Ca2+ stored 
in ER that have a wide range from 103- to ~104 times the [Ca2+]i (Samtleben et al., 2013). 
Further, washing the cells with Ca2+ free ECS and keeping them in it decreased the overall 
availability of Ca2+ that normally perform highly dynamic movement between the extracellular 
environment, cytosol, and cell compartments according to the temporo-spatial signal. 
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Figure 3 MBF in Doses Equal to IC50 Induced [Ca
2+]. 
 
Figure 3: Fura-2 Ca2+ imaging for detecting the effect of the MBF on [Ca2+]i. (A)  The 
DMSO administration to CFPAC-1 cells in a concentration equal to the one used for dissolving 
the drugs did not induce any change in fluorescence ratio, which indicates unchanged [Ca2+]i. (B) 
Administration of MBF in IC50 dose (6 μM) to CFPAC-1 cells significantly increased the [Ca
2+]i. 
(C) Also, Administration of MBF in IC50 dose (8 μM) to HCC-1806 cells caused the same effect 
in increasing the [Ca2+]i. (D) Administration of MBF at a dose of 0.92 μM showed no effect on 
the [Ca2+]i. 
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Figure 4 MBF-Induces Ca2+ Release form ER. 
 
Figure 4: Further Fura-2 assays using CFPAC-1 cells for indicating the mechanism of 
[Ca2+]i increase associated with MBF treatment. (A) The administration of 6 μM of MBF in the 
presence Ca2+ free ECS resulted in an increase of [Ca2+]i, although it was smaller than in the 
presence of normal extracellular Ca concentration  (B) The pre-administration of Thap at a 
concentration of 10 μM to empty the ER Ca2+ store blocked the MBF-induced [Ca2+]i increase. 
MBF was added 13 minutes after pre-administration of Thap, after the [Ca2+]i had almost 
returned to pretreatment concentrations. 
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Figure 5 Percentage increase of [Ca2+] in CFPAC-1 and HCC-1806 cell lines in response to 
MBF adminstration 
 
 
Figure 5: In-vitro administration of MBF at a dose of 6 μM to the CFPAC-1 cells in 
normal Ca2+ containing medium induced ~ 350% increase in the [Ca2+]. Likewise, treating 
CFPAC-1 cells in Ca2+ free ECS with the same concentration caused ~ 100% increase in the 
[Ca2+]. The difference in % increase between the two previous assays might be due to the overall 
scarcity of Ca2+ associated with using Ca2+ free ECS in washing the cells and during imaging. 
Whereas, administration of MBF at a dose of 8 μM to the HCC-1806 cells in normal Ca2+ 
containing medium induced ~ 110% increase in the [Ca2+]. The difference in % increase between 
the two cell lines might be due to the natural differenace between CFPAC-1 cells and HCC-1806 
cells that they orgianted from pancreatic and breast cancer cells respectively. In addition to 
CFPAC-1 cells includes CF mutant gene that alters the ER structure.  
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3.3.3 The effect of MBF Administration on Mitochondrial Membrane Potential 
(MX): 
The previous results showed that MBF-induced more than a 100% increase in the [Ca2+]i. 
To determine whether the change in intracellular Ca2+ had an effect on mitochondrial function, 
the MX in response to MBF treatment was measured using TMRE. Initially, CFPAC-1 cells 
were treated with DMSO in the concentration used for dissolving the drugs. Administration of 
DMSO had no effect on the TMRE fluorescence ratio (F/F0) when compared to baseline levels 
obtained before the administration of DMSO. MBF administration to CFPAC-1 cells at a dose 
equal to IC50 (6 μM) caused a strong hyperpolarization of the MX due to ~ 57% shifting in the 
MX toward the negative side, followed by a small depolarization due to ~ 8% shifting in the MX 
toward the positive side after returning back to the baseline levels obtained before the 
administration of MBF (Figure 6, A-B). Measuring the MX of HCC-1806 cells using the same 
protocol showed a small hyperpolarization of the MX due to ~ 3% shifting in the MX toward the 
negative side, followed by a strong depolarization due to ~ 31% shifting in the MX toward the 
positive side after returning back to the baseline levels obtained before the administration of 
MBF. The administration of the same concentration of DMSO to HCC-1806 cells did not impact 
the MX (Figure 6, C-D). Suggesting that the effect of MBF on MX seen in response to MBF 
above was triggered by MBF-induced Ca2+ release from the ER. To test whether the Ca2+ 
released from the ER in response to MBF administration might be required for inducing a change 
in MX, TMRE was next repeated on cells in which the ER had been previously emptied by Thap 
pretreatment, with the rationale that MBF should no longer be able to trigger a change in MX. 
Therefore, CFPAC-1 cells were pretreated with Thap at a dose of 10 μM for 20 minutes, 
followed by the application of MBF at the IC50 dose, 6 μM. Pre-administration of Thap to 
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CFPAC-1 cells fully blocked the MX hyperpolarization associated with MBF administration 
suggesting that the MBF-induced Ca2+ release from the ER Ca2+ was essential for MX 
hyperpolarization elicited by MBF treatment. Interestingly, Thap administration by itself caused 
MX depolarization, whereas, the rate of depolarization is increased with MBF later 
coadministration (Figure 6, E). Taken together, applying MBF to cancer cells induced 
hyperpolarization of the MX followed by depolarization that varies in the degree of shift from 
the normal MX. Pre-administration of Thap to CFPAC-1 cells completely blocked the MX 
hyperpolarization induced by MBF. Whereas, coadministration   of Thap with MBF boosted the 
MX depolarization response (Figure 6, F). 
 
 
 
 
 
 
 
 
 
 
 
32 
T M R E  Im a g in g  o f  C F -P A C -1  T re a te d  W ith  D M S O
T im e  (S )
F
lu
o
r
e
s
c
e
n
c
e
 R
a
t
io
 (
F
/F
0
)
0 1 0 0 0 2 0 0 0 3 0 0 0 4 0 0 0
0
1 0
2 0
3 0
4 0
D M S O  3  µL
A
T M R E  Im a g in g  o f  C F -P A C -1  T re a te d  W ith  M B F
T im e  (S )
F
lu
o
r
e
s
c
e
n
c
e
 R
a
t
io
 (
F
/F
0
)
0 1 0 0 0 2 0 0 0 3 0 0 0 4 0 0 0
0
1 0
2 0
3 0
4 0
M B F  6  µM
B
  
T M R E  Im a g in g  o f  H C C -1 8 0 6  T re a te d  W ith  D M S O
T im e  (S )
F
lu
o
r
e
s
c
e
n
c
e
 R
a
ti
o
 (
F
/F
0
)
0 1 0 0 0 2 0 0 0 3 0 0 0 4 0 0 0
0
2 0
4 0
6 0
D M S O  3 .5  µL
C
 
T M R E  Im a g in g  o f  H C C -1 8 0 6  T re a te d  W ith  M B F
T im e  (S )
F
lu
o
r
e
s
c
e
n
c
e
 R
a
ti
o
 (
F
/F
0
)
0 1 0 0 0 2 0 0 0 3 0 0 0 4 0 0 0
0
5
1 0
1 5
2 0
M B F  8  µM
D
T M R E  Im a g in g  o f C F -P A C -1
P re -tre a te d  W ith  T h a p  1 0  M  T h e n  M B F  6  M
T im e  (S )
F
lu
o
r
e
s
c
e
n
c
e
 R
a
t
io
 (
F
/F
0
)
0 1 0 0 0 2 0 0 0 3 0 0 0 4 0 0 0
0
2 0 0
4 0 0
6 0 0
E
T h a p . 1 0 µ M
M B F  6  µM
 
%  C h a n g e  in  M ito c h o n d r ia l M e m b ra n e  P o te n tia l
A fte r  M B F  T re a tm e n t
M X  C h a n g e
F
lu
o
r
e
s
c
e
n
c
e
 R
a
ti
o
(F
/F
0
) 
%
 C
h
n
a
g
e
C
F
-P
A
C
-1
 M
X
H
y
p
e
rp
o
la
r i
z
a
t i
o
n
C
F
-P
A
C
-1
 M
X
D
e
p
o
la
r i
z
a
t i
o
n
H
C
C
-1
8
0
6
 M
X
H
y
p
e
rp
o
la
r i
z
a
t i
o
n
H
C
C
-1
8
0
6
 M
X
D
e
p
o
la
r i
z
a
t i
o
n
C
F
-P
A
C
-1
 M
X
D
e
p
o
la
r i
z
a
t i
o
n
 a
ft
e
r
T
h
a
p
 P
re
-t
re
a
tm
e
n
t
C
F
-P
A
C
-1
 M
X
D
e
p
o
la
r i
z
a
t i
o
n
 a
ft
e
r
T
h
a
p
 T
h
e
n
 M
B
F
 T
re
a
tm
e
n
t
-1 0 0
-5 0
0
5 0
1 0 0
F
 
Figure 6 MBF in doses equal to IC50 induces MX hyperpolarization. 
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Figure 6: (A) DMSO administration to CFPAC-1 cells did not impact the MX, as 
evidenced by the flat baseline levels recorded before and after addition of DMSO. (B) Treating 
the CFPAC-1 cells with 6 μM of MBF (equal to IC50) caused a strong hyperpolarization of the 
MX by shifting in the MX ~ 57% toward the negative side, followed by a small, depolarization 
by 8% shifting in the MX toward the positive side after returning back to the baseline levels 
obtained before the administration of MBF. (C) Administration of DMSO to HCC-1806 cells did 
not result in a change of MX from pretreatment levels. (D) Treating the HCC-1806 cells with 8 
μM of MBF (equal to IC50) induced a small hyperpolarization of the MX by shifting in the MX ~ 
3% toward the negative side, followed by a strong depolarization by 31% shifting in the MX 
toward the positive side after returning back to the baseline levels obtained before the 
administration of MBFE) Pretreatment of CFPAC-1 cells with Thap at a dose of 10 μM blocked 
the hyperpolarization of MX induced by MBF. Thap caused MX depolarization by 23% shifting 
in the MX toward the positive side that depolarization increase to 57% by adding MBF at a dose 
of 6 μM. D) The % change of MX induced by MBF administration into CFPAC-1 and HCC-
1806 at a dose of 6, 8 μM respectively. The hyperpolarization effect showed as increase of the 
column length toward the negative side of the Y axis (downward) and the depolarization effect 
showed an increase of the column length toward the positive side of the Y axis (upward). Pre-
administration of the Thap in a dose of 10 μM blocked the hyperpolarization resulted from MBF 
administration and strengthened the depolarization effect 
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3.4 Discussion: 
To determine the effect of MBF on the Ca2+ signaling in CFPAC-1 and HCC-1806 cells, 
the [Ca2+]i was determined after treating cells with previously established IC50 doses for MBF. 
MBF was introduced into the market as antihypertensive drug that has a greater affinity to block 
the TTCC over the LTCC , which inhibits Ca2+ induced Ca2+ release in cardiac and arterial 
smooth muscles (Ottolia et al., 2013),  Our results showed that MBF induces a [Ca2+]i increase in 
cancer cells. The increased [Ca2+]i can originate from different sources. Ca
2+ can enter the cells 
from the extracellular environment or can be released from intracellular stores (ER and 
mitochondria). 
Initially, the intracellular [Ca2+]i increase was investigated using Ca
2+ imaging. The 
results indicated that treating the HCC-1806 and CFPAC-1 cells with the IC50 doses of MBF (8 
and 6 µM respectively) increased the [Ca2+]i more than 100% within ~1.5 minute of MBF 
administration. Furthermore, the Ca2+ imaging was repeated for identifying the mechanism by 
which the MBF induces [Ca2+]i increase. Initially, the possibility of Ca
2+ entrance from outside 
the cell was examined by repeating the Ca2+ imaging using a Ca2+ free ECS. Administration of 
MBF into CFOAC-1 cells in Ca2+ free medium induced ~ 100% increase in the [Ca2+]i, which 
excluded the suggestion that the increase of [Ca2+]i induced by MBF was due to the influx of the 
Ca2+ from the extracellular environment. Excluding the extracellular Ca2+ source left us with two 
other possibilities, namely that MBF-induced Ca2+ release from the ER or the mitochondria, 
which are the major cytosolic Ca2+ stores. 
For identifying the intracellular source of Ca2+ release caused by MBF administration, the 
Ca2+ imaging was repeated using Thap pretreatment in a dose of 10 μM followed by adding 
MBF at the IC50 dose. Interestingly, Thap treatment raised the [Ca
2+]i and blocked the MBF-
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induced [Ca2+]i increase, when MBF was subsequently added to the cells after Thap 
pretreatment. The Thap induced [Ca2+]i increase lasted for ~ 10-15 minutes and then returned 
back to normal levels before adding MBF (Figure 4, B). Thap is a known SERCA blocker, which 
normally pumps Ca2+ back into the ER; Thap treatment, therefore, resulted in emptying the ER 
Ca2+ stores. This directly suggested that MBF-induced Ca2+ release from the ER. A similar effect 
was reported in leukemia cell lines treated with MBF (Huang et al., 2015; Zhang et al., 2006). 
The MBF IC50 doses used in Ca
2+ imaging were reported to block most types of voltage 
gated Ca2+ channels (L and TTCC) (Martin et al., 2000), voltage-gated Na+ channels (Eller et al., 
2000; McNulty and Hanck, 2004), and volume-activated Cl- channels (Nilius et al., 1997) and . 
The blocking of TTCC that overexpressed in cancer cells in addition to multiple ion channels 
affects the ionic homeostasis in cancer cells and might contribute to stressing the ER causing 
Ca2+ release. Depletion of Ca2+ from the ER may severely impact Ca2+ dependent chaperones in 
the ER, resulting in the accumulation of miss-folded protein in the ER that might trigger 
apoptosis. Further, impacting the ER chaperones likely reduces the cell’s ability to produce 
proteins and enzymes essential for maintaining cellular biological functions, especially in highly 
active cancer cells (Coe and Michalak, 2009). 
Treating CFPAC-1 cells with MBF concentrations < 1 µM did not induce Ca2+ release 
(Figure 3, D), although a dose of 1 µM MBF is higher than the required for blocking TTCC. 
Also, MBF at a concentration of 1 µM or less did not show any effect on cancer cells’ viability 
in MTT assays. That suggests the MBF-induced Ca2+ release from the ER is required for 
inhibiting the cancer cells’ viability Furthermore, the MBF concentrations ≤ 1 µM that able to 
block the TTCC did not show any change in the [Ca2+]i suggesting that the MBF-induced Ca
2+ 
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release from the ER was not resulting from blocking of TTCC. and that Ca2+ release not only 
produced by blocking TTCC. 
We suggested that the MBF-induced Ca2+ release from the ER might affect the 
mitochondria through the mitochondria ER-associated membranes, which play a crucial role in 
Ca2+ transport and signaling between the ER and mitochondria (Morciano et al., 2018). 
Therefore, the effect of MBF was investigated as an indicator of the effect of MBF on the 
mitochondrial soundness. Treating CFPAC-1 and HCC-1806 cells with MBF at the IC50 dose (6 
and 8 µM respectively) showed MX hyperpolarization followed with depolarization. 
Interestingly, pretreating the cells with Thap (10 µM) before MBF blocked the hyperpolarization 
effect of MBF. 
It is possible that MBF is disrupting the ER homeostasis that affects protein synthesis in 
the ER and triggers the unfolded protein response. Consequently, the cells would suffer from 
oxidative stress due to a leakage of reactive oxygen species (ROS) form the mitochondrial 
electron transfer system, causing MX hyperpolarization. Eventually, the mitochondria would 
collapse, and cells would undergo subsequent apoptosis. A similar effect was reported in 
leukemia cells treated with ER stressors econazole and tunicamycin, but Thap showed neither 
MX hyperpolarization nor ROS release (Zhang et al., 2006). 
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3.5 Conclusion: 
Treating cancer cells with the IC50 doses of MBF-induced ER Ca
2+ release in cancer cells 
and a more than 100% increase in [Ca2+]i, while using 0.92 µM of MBF did not show any change 
in [Ca2+]i. Also, in-vitro administration of MBF affected the MX and caused MX 
hyperpolarization followed by depolarization, which is considered as a pre-apoptotic sign. MBF-
induced ER Ca2+ release was necessary to inhibit cancer cell viability and to impact the MX by 
hyperpolarization. 
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4- CHAPTER 3 
MBF Induces Apoptosis via Releasing Ca2+ from Thapsigargin Sensitive Stores 
 
4.1 Introduction: 
The effect of anticancer drugs varies according to the mechanism of action. Because the 
cancer cells exhibit uncontrolled proliferation, some effective anticancer drugs, especially the 
chemotherapeutics, target the cell division machinery that inhibits cell division and triggers 
apoptotic cell death. There are other targets for specific kinds of cancers, such as antiestrogenic 
agents for treating estrogen sensitive breast cancer cells and targeting the lipid metabolism 
(Ariazi et al., 2011; Daher et al., 1990; Saxena et al., 2017). Apoptosis is the final and desirable 
endpoint for cancer cells after exposure to anticancer drug, because it is a normal process that 
ends with breaking down the cell into apoptotic bodies, which are recognized and engulfed by 
macrophages.  
Apoptosis is defined as genetically programmed cell death that normally happens in 
multiple life stages from embryonic development until aging and can also occurs under 
pathological conditions. The term apoptosis is derived from the Greek and means ‘falling off’ as 
in leaves falling off a tree, and indicates the phenomenon by which a cell enters its own 
termination processes (Kerr et al., 1972). 
Apoptosis is associated with many morphological changes, including abolishing the 
membrane symmetry and attachment, blebbing of the plasma membrane, condensation of 
cytoplasm and nucleus, and DNA internucleosomal cleavage. One of the earliest events of 
apoptosis is the loss of plasma membrane symmetry. Thus, the phospholipid phosphatidylserine 
(PS) is translocated from the inner leaflet of the plasma membrane into the outer leaflet and 
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exposed to the extracellular environment. The exposed PS remains on the external leaflet of the 
plasma membrane acting as a marker of the apoptotic cell or the broken down apoptotic bodies to 
be identified and phagocytosed by macrophages. 
The microscopic changes of an apoptotic cell can be distinguished in several stages. 
Initially, in early apoptosis, cells shrink and become smaller in size, resulting in cytoplasm 
condensation with tightly packed organelles. Also, the chromatin undergoes irreversible 
condensation (pyknosis) at early apoptosis. Then, the plasma membrane shows extensive 
blebbing, followed by destructive fragmentation of the nucleus (karyorrhexis) caused by 
activated endonucleases. Eventually, the cell is fragmented into apoptotic bodies in a process 
called “budding.” The apoptotic bodies include tightly packed organelles, with or without a 
nuclear fragment, in an intact plasma membrane, where the integrity of organelles is still 
conserved. Subsequently, the apoptotic bodies are phagocytosed by macrophages, parenchymal 
cells, or neoplastic cells and undergo further degradation by phagolysosomes (Casciola-Rosen et 
al., 1996; Elmore, 2007) (Figure 7). 
Suggesting that MBF might induce apoptosis. The apoptosis assay was performed on 
CFPAC-1 cells treated with MBF at the IC50 dose (6 μM) for 48 h and at higher concentrations 
for 12 h to determine the MBF effect at time longer and shorter than doubling time. Furthermore, 
to test whether MBF-induced Ca2+ release from the ER might be the trigger for the apoptosis, 
MBF treatment was next repeated on cells in which the ER had been previously emptied by Thap 
pretreatment, with the rationale that MBF should no longer be able to induce apoptosis. 
Annexin V is a Ca2+- dependent phospholipid-binding protein and has a high affinity for 
binding the exposed PS on the external surface of the apoptotic cell (Van Engeland et al., 1996; 
Vermes et al., 1995). The fluorophore-conjugated Annexin V (e.g., Annexin V-FITC) can be 
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detected by excitation-emission properties of the fluorophore. This technique can be used for 
detecting and sorting apoptotic cells through flow cytometry with high sensitivity and accuracy. 
Necrosis (from a Greek word meaning “death”) is a form of cell injury that results in 
premature cell death in a living tissue, which usually happens by autolysis. Necrosis, in contrast 
to apoptosis, is an abnormal condition mostly caused by an external factor that affects the cell or 
tissue, such as toxins, infection, or trauma that triggers unregulated digestion of the cell 
components and is associated with an inflammatory response. Also, necrosis differs 
morphologically from apoptosis. The necrotic cell initially undergoes swelling, followed by 
plasma membrane collapse and cell lysis (Proskuryakov et al., 2003) (Figure 6).   
Propidium iodide (PI) is a fluorescent DNA intercalating agent that is widely used for 
detecting necrotic cells. PI cannot enter through the intact plasma membrane of the healthy cells 
or cells in the early to intermediate stages of apoptosis. Losing the integrity of the plasma and 
nuclear membranes allows entrance of PI into the cell, resulting in the staining of DNA in the 
case of necrosis and late apoptosis. The excitation-emission characteristics of PI can be used to 
detect cells in late apoptosis and necrosis using the flow cytometry (Cummings et al., 2012).  
The PS exposure in the apoptotic cell allows a prompt recognition by the phagocytes, 
which achieve a quick phagocytosis with minimal complications for the surrounding tissue 
(Bratton et al., 1997). 
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Figure 7 The morphological changes of apoptosis versus necrosis. 
 
Figure 7: The different morphological changes of a cell undergoing apoptosis or 
necrosis. Apoptotic cell shows membrane budding and exposed PS on the extracellular side of its 
membrane leaflets, increasing membrane permeability and cell shrinkage. Finally, the cell 
undergoes fragmentation into apoptotic bodies that will be engulfed by macrophages. While the 
necrotic cell shows swelling and loss of its membrane integrity initially, the cell will eventually 
rupture with severe tissue reactions that induce an inflammatory response. 
 
 
 
 
 
http://digitalvortex.info/plasma-diagram-a2be12b02b/ 
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4.2 Materials and Methods: 
4.2.1 Apoptosis Assay: 
CFPAC-1 cells were grown in 35 mm plates at a seeding density  of ≃ 0.3 x 106 in 2 mL 
of suitable medium. Various doses of MBF and different expousuer time were applied to 
detrmine the MBF effect at time longer and shorter than doubling time. Further, to test whether 
MBF-induced Ca2+ release from the ER might be the trigger for the apoptosis, MBF treatment 
was next repeated on cells in which the ER had been previously emptied by Thap pretreatment 
After 24 h incubation in standard conditions, one plate was treated with 6 µM of MBF (IC50 
dose) and another plate with 6 µL of DMSO (control) for 48 h; One plate was treated for 12 h 
using each of the following regimes, DMSO 0.1 % for 30 minutes then MBF 50 µM was added, 
DMSO 0.1 % for 30 minutes then MBF 20 µM was added, Thap 10 µM for 30 minutes then 
DMSO 0.2 % was added, Thap 10 µM for 30 minutes then the MBF 20 µM was added, Thap 10 
µM for 30 minutes then the cells were washed with 1x DPBS followed by adding MBF 20 µM,  
and the control was treated with DMSO 0.3%. Further, three untreated plates were kept for flow 
cytometer controls. The cells were detached from the plate by adding 0.7 mL of trypsin 0.25 % 
(Corning®) for 6 minutes then 0.6 mL of medium containing 10 % FBS was added for stopping 
the effect of trypsin. The cells were pelleted using centrifugation at 120 xg for 5 minutes, then 
the medium was removed, and the cells were washed with DPBS and re-pelleted. The 
TACS® Annexin V-FITC Kit (Trevigen Inc, MD, USA) was used for apoptosis and necrosis 
detection. The cells were resuspended and stained with Annexin V-FITC and Propidium Iodide 
according to the kit's protocol. The three non treated plates were kept for assigning the standards 
of the flow cytometer machine and treated as follows: non-stained, only Annexin V-FITC 
stained, and only Propidium Iodide stained. The cells were screened by BD LSRFortessaTM 
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(BD Biosciences, CA, USA). The flow cytometry data were analyzed using FlowJo software 
(FlowJo LLC, OR, USA). The data obtained from the FlowJo software were expressed as 
percentage of the cells in each status (early apoptosis, late apoptosis, and necrosis). The 
calulations for removing the percentage of cells affected by DMSO were prformed by Microsoft 
Excel and the final data were analyzed and plotted using GraphPad Prizm 6. The assay was run 
for 10000 cells for the machine controls and 30000 cells for the DMSO controls and treated 
cells. 
4.2.2 Statistical Analysis: 
GraphPad Prism 6 software was used for data plotting, graph building, and statistical 
analysis. The data were calculated with Microsoft Excel, then fitted using the GraphPad column 
analysis as a percentage of the overall population, which was 104 cells for controls and 3 x 104 
for treated cells. 
 
4.3 Results: 
4.3.1 AnnexinV/PI Assay for Detection of MBF-Induced Apoptosis and the Role of 
MBF-Induced Ca2+ Release in the Apoptosis of CFPAC-1 Cells: 
Exposure of the phosphatidylserine (PS) in the external leaflet of the plasma membrane 
during the early and intermediate stages of apoptosis can be detected by annexin V conjugation. 
Also, the apoptotic bodies and microparticles are stained with the annexin V (Hristov et al., 
2004). The highly fluorescent annexin V bound to the exposed PS was excited at ~ 490 nm and 
emission was collected at ~ 490-535 nm. Necrotic and the late apoptotic cells would lose their 
membrane integrity, resulting in the diffusion of PI stain into the cells where it would stain 
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necrotic cell nuclei due to its DNA intercalating capacity. PI can subsequently be detected by 
exciting it at ~ 490 nm and collecting the emission at ~ 535-620 nm. 
Treating CFPAC-1 cells with the MBF IC50 dose (6 µM) for 48 h increased the number 
of cells that expressed apoptotic markers by 9% (apoptosis 2%, and late apoptosis 7%) versus 
DMSO control (Figure 8, D, E, L). Furthermore, exposing CFPAC-1 cells to 50 µM of MBF for 
12 h dramatically increased the expression of cells with apoptotic markers to 43% (almost no late 
apoptosis or necrosis, 2%) versus DMSO control (Figure 8, F, G, L). Moreover, MBF 
administration at a dose of 20 µM for 12 h significantly increased the number of cells with 
apoptotic markers up to 38% versus DMSO control, but most of those cells were in the late 
apoptosis phase (30% of 38%) (Figure 8, F, H, L). Also, Treating the cells with 10 µM of Thap 
for 12 h induced apoptosis only for 11% of cells (apoptosis 8%, and late apoptosis 3%) (Figure 
7, F, I, L).  Interestingly, pretreating the cells with 10 µM of Thap for 30 minutes then adding 20 
µM of MBF and keeping them together for 12 h decreased the number of cells with apoptotic 
markers from 38% (MBF only) to 15%. Furthermore, the cells with MBF only treatment showed 
late apoptosis (30%) more than early and intermediate apoptosis (8%), while the combination 
treatment with Thap and MBF showed opposite results (apoptosis 11%, and late apoptosis 4%) 
(Figure 8, F, J, L). Whilst, washing out the Thap after pretreating the cells for 30 minutes then 
adding MBF alone for 12 minutes also reduced the number of cells with apoptosis markers to 
22% (apoptosis 10%, and late apoptosis 12%) versus 38% in MBF only treatment (Figure 8, F, 
K, L). Thus, removing Thap after 30 minutes of treatment brought back the strong apoptotic 
action of MBF but still less than the effect of sole administration of MBF (Figure 8, L). 
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Figure 8 MBF-induced apoptosis in CFPAC-1 cells via Ca2+ release from Thap sensitive stores. 
 
 
Figure 8: Detection of MBF-induced apoptosis in CFPAC-1 cells using AnnexinV/PI 
staining and flow cytometry the degree of AnnexinV-FITC expression was plotted on the X, 
while the PI expression was plotted on the Y axis. (A-C) Non-treated machine controls; the cells 
in (A) were not stained, while the cells in (B) and (C) were stained with AnnexinV and PI 
respectively. The controls were run for adjusting the gates’ voltages that dependently controls the 
wavelength of maximum emission.  (D- E) Treating cells with MBF at a dose of 6 µM for 48 h 
showed 9% increase in cells with apoptotic markers versus DMSO treated control cells. (F, G) 
The single treatment of CFPAC-1 cells with MBF showed a significant increase in the cells that 
express apoptosis markers versus DMSO treated control cells; this increase showed dose-
dependency (38% and 43% for MBF 20 and 50 µM, respectively). (H) Cells that were treated 
 
49 
with 10 µM of Thap showed expression of apoptosis markers in 11% of cells. (I- K) Pretreating 
the cells with 10 µM of Thap decreased the apoptotic effect of MBF. Coadministration of MBF 
and Thap for 12 h, by adding 10 µM of Thap for 30 minutes prior to adding 20 µM of MBF to 
CFPAC-1 cells markedly decreased the percentage of cells expressed apoptosis to 15% versus 
38% with MBF single treatment. Whereas, washing the cells with DPBS after pretreating the 
cells with 10 µM of Thap for 30 minutes and prior to administrating of 20 µM of MBF alone for 
12 h partially restored the apoptotic effect of MBF and mitigated the apoptosis blockage effect of 
Thap, 22% of cells expressed apoptosis versus 38% with coadministration of MBF and Thap 
together for 12 h. (L) The column graph summarizes the results of the apoptosis assays. Treating 
CFPAC cells with MBF resulted in a dose-dependent expression of apoptosis markers that varied 
from early to intermediate apoptosis, and to late apoptosis. A single administration of 10 µM of 
Thap significantly inhibited the apoptotic effect of MBF. 
 
4.4 Discussion: 
As indicated in chapter 1, MBF potentially inhibited different cancer cells’ viability at 
low concentrations. Conducting a MTT assay over 48 h of treatment allowed enough time for the 
cells to perform one to two replication cycles that also allowed MBF to impact the viability of 
the cells or halt their division or both. To test whether the inhibitory effect of MBF on the cancer 
cells caused by inducing apoptosis or necrosis, apoptosis assay was conducted. 
An apoptosis assay was performed in order to investigate the apoptotic effect of MBF on 
CFPAC-1 cells. It is important to note that the desirable outcome of an anticancer drug in this 
context was to induce apoptosis, thereby triggering programmed cell death without adverse 
tissue reaction or inflammation commonly seen during necrotic cell death. The highest 
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concentration of MBF (50 µM) showed massive apoptotic effect (43%) after 12 h of treatment 
that can be identified as very fast early apoptosis. Treating the cells with MBF at a dose of 20 
µM induced apoptosis in 38% of cells, and most of the cells showed late apoptosis (30%). Taken 
together, raising the dose of MBF up to 50 µM accelerated the apoptosis until the cells 
completely disintegrated into apoptotic bodies. The membranes of the apoptotic bodies, which 
are parts of the apoptotic cell membrane, contain externally exposed PS, therefore they were 
stained with Annexin V-FITC. While apoptotic bodies do not include nuclei or even intact DNA 
that they could not be stained with PI. Consequently, Apoptotic bodies expressed Annexin V-
FITC stain only and were showed by the flow cytometer on the X axis  similar to the early 
apoptosis (Hristov et al., 2004). 
Further, it was shown that late apoptosis was predominant at lower concentration of MBF 
(Figure 8), suggesting a later onset of apoptosis. Interestingly, Thap coadministration with MBF 
mitigated the apoptotic effect of MBF. Pretreating the cells with Thap at a dose of 10 µM, then 
keeping Thap with MBF (20 µM) as a combination for 12 h, decreased the apoptotic effect of 
MBF by 61%. Interestingly, transient pretreatment of cells with Thap for 30 minutes, followed 
by removal of Thap and addition 20 µM of MBF alone for 12 h resulted a lower degree of 
apoptosis inhibition (42%) than when Thap and MBF were coadministered (61%).  
Thap is a SERCA pump inhibitor that prevents the Ca2+ reuptake by the ER, resulting in 
emptying of Ca2+ stored in the ER. Thap is an ER stressor that could induce apoptosis in small 
fraction of the cells, only 2%, after 12 h of treatment with a dose of 10 µM. The results 
suggested that emptying the Ca2+ stores in the ER may potentially diminish the MBF-induced 
apoptosis in cancer cells, pointing towards the importance of MBF-induced Ca2+ release for the 
ER for killing of CFPAC-1 cancer cells. 
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4.5 Conclusion: 
MBF induces apoptosis in CFPAC-1 cells in a dose dependent fashion. MBF 
administration to CFPAC-1 cells at IC50 dose (6 µM) caused little apoptotic effect (9%); while a 
dose of 50 µM induced massive and fast apoptosis (43%). Further, MBF at a dose of 20 µM 
generated significant apoptosis (38%), which was diminished by Thap coadministration. 
Inhibiting the ER Ca2+ reuptake by Thap blocked the MBF-induced apoptosis, which suggests 
that the ER Ca2+ store is important for maintaining the strong apoptotic effect of MBF. 
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5- CHAPTER 4 
THE ROLE OF INTRACELLULAR CALCIUM RELEASE FROM ER IN 
MIBEFRADIL EFFECTS TO LIPID METABOLISM 
 
5.1  Introduction: 
Lipid droplets (LDs) are the principal cellular organelles for lipids storage that either are 
acquired from the nutrition or produced by the cell during the normal metabolism. Excessive 
lipid storage in the form of LDs is associated with the pathogenesis of many diseases, such as 
atherosclerosis, obesity, and diabetes. Therefore, studying the structure-function and biological 
dynamics of the LDs on the cellular level is of great interest. Furthermore, the latest studies not 
only investigate LDs dynamics but also try to correlate changes in LD with those in other 
organelles [e.g., peroxisomes, endosomes, endoplasmic reticulum (ER), plasma membrane and 
mitochondria] (Guo et al., 2009). 
The final synthesis of LDs is performed in the ER due to the presence of the final step 
enzymes (mainly diglyceride acyltransferase, DGAT) of the synthetic pathways that mediate the 
formation of neutral lipids (particularly triacylglycerols and steryl esters.) The saturation level of 
the lipid pool within the ER membrane bilayer controls the release of the lipids by budding 
toward the cytosolic side. The cell can utilize the lipids stored in LDs under starvation 
circumstances through autophagy in a process involving autophagic proteins (Atgs) (Hashemi 
and Goodman, 2015). 
Multiple genes encoding for enzymes contributing in fatty acid and cholesterol 
biosynthesis are targets of SREBPs (sterol regulatory element-binding proteins), which are a 
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family of transcriptional factors that are fundamental for maintaining lipid homeostasis in 
healthy cells (Bengoechea-Alonso and Ericsson, 2007).  
Abnormal activation of SREBPs can be involved in many diseases such as fatty liver, 
obesity, and insulin resistance and could contribute to cancer development (Shao and 
Espenshade, 2012).  
SREBPs are synthesized in the ER as inactive precursors and stay in the ER membrane in 
association with SREBP-cleavage-activating protein (SCAP) and activated in response to a low 
level of cholesterol or membrane phosphatidylcholine. Further, SREBPs contribute to the 
downstream regulation of growth signaling through the PI3K (phosphatidylinositol-3-kinase) 
pathway. 
The ability of the cancer cells to perform a high rate of lipid production by de novo 
lipogenesis was shown. Further, the rate of de novo lipogenesis was correlated with the tumor 
stage, in that early stages showed a higher rate of lipogenesis. The high rate of lipogenesis is 
required for the cancer cells for the formation of the phospholipids blocks for new cell 
membranes, as a source of energy storage, and for lipid signaling, especially the growth factor 
signaling that depends on PI3P (phosphatidylinositol (3,4,5)-trisphosphate) and PI3K (Baenke et 
al., 2013).  
Furthermore, the overexpression of hypoxia-inducible factors (HIFs) due to the activation 
of oncogenes and the hypoxia associated with the cancer mass was identified to enhance the lipid 
biosynthesis (Santos and Schulze, 2012). 
The altered lipid metabolism, including a high lipogenesis rate, was found to contribute 
to cancer cell growth, proliferation, energy homeostasis, resistance to oxidative stress, resistance 
to energy stress, and signaling functions of lipids. Therefore, tackling the lipid metabolism in 
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cancer cells has emerged as a promising target for novel anticancer drugs (Menendez and Lupu, 
2007; Santos and Schulze, 2012; Saxena et al., 2017). 
In response to nutrient starvation, cancer cells can utilize the lipid stored in LDs by 
recruiting the autophagic machinery, including autophagy related 5 (Atg5) protein (Baenke et al., 
2013). This lipid mobilization mechanism was consequently called ‘macrolipophagy’. Therefore, 
the accumulation rate of LDs increased when macrolipophagy was suppressed. (Singh et al., 
2009). 
The LDs within cells can be preserved through gentle? fixation using formaldehyde 
(10%) and then stained with oil red O, which is a fat-soluble red stain. To achieve a quantitative 
estimation of the amount of oil red O stained LDs in an area of interest, the cytoplasm and nuclei 
are stained with a water-soluble hematoxylin dye that gives them a blue color (Light blue for the 
cytoplasm and dark blue for the nucleus). Using a digital microscopic imaging approach, LDs 
staining can be quantified against the whole cell area as a background (Fukumoto and Fujimoto, 
2002; He et al., 2004). 
Glycerol is produced by cells as a by-product of lipolysis whereas the cells utilize the lipid stores 
upon need. Cells recruit lipolytic enzymes to break down the lipid stored in LDs into fatty acids 
and glycerol. The glycerol produced by the cells grown in a cell culture dish will diffuse outside 
of the cells and accumulate in the medium (Smith et al., 1979). 
Glycerol Kinase (GK) exploits ATP into ADP for phosphorylating the glycerol producing 
G-1-P (glycerol-1-phosphate). Consequently, GPO (glycerol phosphate oxidase) oxidizes G-1-P 
to DAP (dihydroxyacetone phosphate) and hydrogen peroxide (H2O2). The H2O2 is coupled with 
ESPA (4-aminoantipyrine (4-AAP) and sodium N-ethyl-N-(3-sulfopropyl) m-anisidine) to form 
a quinoneimine dye by POD (peroxidase). The OD of the produced quinoneimine dye can be 
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measured at 540 nm as an indicator of the glycerol concentration and to be quantified against 
standards with known glycerol concentration (Barham and Trinder, 1972; Trinder, 1969). 
To test whether MBF might affect the lipid metabolism, oil red O stain and lipolysis 
assay were performed on cancer cells treated with MBF, with the rationale that LDs number and 
lipolysis rate should be impacted by MBF treatment due to its previously identified effect on 
Ca2+ signaling, ER Ca2+ stores, and mitochondria that all fundamentally contribute to lipid 
metabolism in cancer cell. 
 
5.2 Materials and Methods: 
5.2.1 Oil Red O Stain and Imaging: 
The cells were grown in 35 mm plate at a seeding density of ≃ 0.3 x 106 and 0.8 x 106 
Cells/ plate for CFPAC-1 and HCC-1806 cells, respectively. After 24 h incubation in standard 
condition, the medium was replaced with medium contains MBF at the IC50 (6 and 8 µM, 
respectively) for treated plates or DMSO for control plates. The plates were incubated for 1, 3, 6, 
12, 24, 36 h in standard condition, 2 plates for each time point (treated and control). At each time 
point, the medium was removed, and the cells were washed twice with 1x DPBS. The cells in 
each plate were fixed with 1 mL of 10% formaldehyde for 30 minutes, then were washed twice 
with deionized water. The fixed cells were treated with 1.5 mL of 60% isopropanol for 5 
minutes. After isopropanol removal, 1.5 mL of 60% oil red O stain working solution was added 
for 20 minutes for staining the lipid droplets. The stained cells were washed with deionized water 
until the water rinsed off clear. For staining the cytoplasm and nuclei in blue, the cells were 
treated with 1.5 mL hematoxylin for 1 minute then to be washed with deionized water until the 
water rinsed off clear. All the staining procedures were done at room temperature. 
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Using a ZEISS Axio Imager A1 polarized light microscope equipped with AxioCam 
MRc 5 camera and connected to Zeiss AxioVision Rel. 4.8 software, the cells were imaged at 
1000x total magnification (100x oil objective lens). All plates were imaged in the same manner; 
10 images were taken from each plate, starting in the upper half of the plate from left to right, 
then the lower half from right to left, and one image from the center (Figure 9). The images were 
digitally analyzed using ImageJ software. The ImageJ ratiometric analysis was based on 
detecting the intensity of the red color (lipid droplets) to blue color (the cytoplasm and the 
nucleus). The red over blue ratios of the MBF treated cells versus DMSO treated control cells 
were statistically analyzed to identify the percentage change of the amount of lipid droplets per 
cell. 
 
5.2.2 Glycerol Assay: 
For detecting the MBF-induced lipolysis in CFPAC-1 cells, a Glycerol assay kit (Sigma-
Aldrich) was used for colorimetric detection of the glycerol amount in the medium after MBF 
treatment. The CFPAC- 1 cells were seeded at a density of ~ 0.5 x 106 cells in 1 mL of suitable 
medium per well into 12 well plates. After 24 h incubation in standard conditions, column 1 (N = 
4) was consecutively treated with medium contains DMSO 0.3% (-ve control), column 2 was 
pretreated with DMSO 0.1 % for 30 minutes then MBF 20 µM was added, column 3 was 
pretreated with Thap 10 µM for 30 minutes then DMSO 0.2 % was added, column 4 was 
pretreated with Thap 10 µM for 30 minutes then the MBF 20 µM was added, and column 5 was 
pretreated with Thap 10 µM for 30 minutes then the cells were washed with 1x DPBS followed 
by adding MBF 20 µM. After incubating the plates in standard conditions for 12 h, the medium 
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was collected in autoclaved 1.7 mL Eppendorf tubes and centrifuged at 8000 × g, and the 
supernatant was stored at -80 oC. 
The samples were transferred into 96 well plates (Corning®), and the glycerol assay was 
performed according to the company's manual. The ODs were read for individual wells using a 
microplate reader at wavelength 570 nm.  
 
5.2.3 Statistical Analysis: 
GraphPad Prism 6 software was used for data plotting, graphing, and statistical analysis. 
ANOVA and t-test (non-paired) were used to analyze the statistical significance of the data. The 
curves were fitted using GraphPad column analysis. Results are expressed as mean±SE (standard 
error). Statistically, the P values for significant differences were indicated as follows: non-
significant (ns) (P > 0.05), * (P ≤ 0.05), ** (P ≤ 0.01), *** (P ≤ 0.001), and **** (P ≤ 0.0001). 
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Figure 9 Oil Red O imaging technique. 
 
Figure 9: The 35 mm oil red O stained plate was imaged at 1000x total magnification 
(100x oil objective lens) using a polarized light microscope. For each plate, 10 fields were 
assigned starting in the upper half of the plate from left to right, then the lower half from right to 
left, and one field from the center. The 10 images from each plate underwent ImageJ radiometric 
analysis based on detecting the intensity of the red color (lipid droplets) to blue color (the 
cytoplasm and the nucleus). 
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5.3 Results: 
5.3.1 Time-Dependent Changes in LDs Upon MBF Treatment with IC50 Dose: 
The ImageJ digital analysis was performed for oil red O stained HCC-1806 cells treated 
with the IC50 dose of MBF (8 µM) versus DMSO treated cells. The analysis showed a significant 
decrease in the red (LDs) over blue (cytoplasm and nucleus) ratio in 3, 6, 12, 24, 36 h of 
treatment, which indicates a decrease in the LDs number and/or volume. Treatment of HCC-
1806 cells for 1 h did not show a significant difference (Figure 10, A, B). In CFPAC-1 cells 
treated with 6 µM of MBF, the analysis of oil red O staining showed a significant decrease in the 
red over blue ratio after 12, 24, 36 h of treatment versus the DMSO treated control cells, whereas 
there was no significant change in the red over blue ration after 1, 3, 6 hrs. of treatment (Figure 
10, C, D). 
 
5.3.2 The Effect of MBF on the Rate of Lipolysis in CFPAC-1 Cells: 
The oil red O stain indicated a decrease in the LDs after MBF treatment. To investigate 
whether MBF-induced lipolysis, the glycerol concentration was measured in the cells’ medium 
after MBF treatment as an indicator of lipolysis. Treating CFPAC-1 cells with MBF in a dose 
equal to the IC50 (6 µM) resulted in a significant increase in the glycerol concentration compared 
to the DMSO treated control cells, but only after 36 h of treatment (Figure 11, A); other 
treatment time points did not show any significant changes in glycerol concentration. Suggesting 
that MBF might induce lipolysis that triggered by the MBF-induced Ca2+ release from the ER 
Ca2+ stores. MBF treatment was next repeated on cells in which the ER had been previously 
emptied by Thap, with the rationale that MBF should no longer be able to induce lipolysis. 
Treating cells with 20 μM of MBF for 12 h did not result in a change in the glycerol 
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concentration and pretreating the cells with Thap then combining MBF did not show difference 
in the glycerol conc, as well; the amount of glycerol produced by the cells after 12 h of treatment 
remained the same as in control (DMSD treated) cells for all treatment regimes except MBF at a 
dose of 50 μM. Only the cells treated with 50 µM of MBF showed significant increases in 
glycerol conc (Figure 11, B). 
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D-     Oil-O-Red Staining of HCC-1806 Cells after MBF Time Points Treatment 
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Figure 10 MBF decreased the abundance of LDs in HCC-1806 and CFPAC-1 cells. 
 
 
B-   Oil-O-Red Staining of CFPAC-1 Cells after MBF Time Points Treatment 
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Figure 10: (A) Oil red O stain of HCC-1806 cells after MBF treatment at the IC50 dose 
(8 μM) at different time points showed a significant decrease of the red over blue intensity at 3, 
6, 12, 24 and 36 h of treatment. (B) Selected images from the MBF treated HCC-1806 cells at 
different time points. Images were captured using an inverted microscope with total 
magnification power 1000 x. (C) The oil red O stain of CFPAC-1 cells after time point treatment 
of MBF at the IC50 dose (6 μM) shows a significant decrease of the red over blue intensity at 12, 
24 and 36 h of treatment. The decrease in red over blue intensity indicates a reduction in the LDs 
size and/or numbers. (D) Selected images from the MBF treated CFPAC-1 cells at different time 
points. Images were captured using an inverted microscope with total magnification power 1000 
x. 
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Figure 11 MBF-induced lipolysis in CFPAC-1 cells. 
 
Figure 11: The Glycerol assay is measuring the glycerol concentration in the medium as 
an indication for lipolysis. (A) CFPAC-1 cells treated with MBF at the IC50 dose (6 μM) for 
different time points (6, 12, 24, and 36 h) showed a significant increase in the glycerol conc (per 
~ 0.2 x 106 cells) only after 36 h treatment, with about doubling the glycerol concentration from 
about 45 μM in DMSO treated control cells to about 100 μM with MBF treatment. (B) CFPAC-1 
cells treated with 50 μM of MBF produced a significantly higher amount of glycerol compared 
with DMSO treated cells (control). Treating the cells with 20 μM of MBF for 12 h did not 
change the glycerol conc and pretreating the cells with Thap then combining the MBF did not 
produce any change in glycerol conc, as well.  
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5.4 Discussion: 
As mentioned in the introduction, a high rate of lipogenesis is a crucial process within the 
cancer cell. Cancer cells store the produced lipids in the form of LDs for multiple biological 
purposes. Because the ER is the major organelle for LDs formation and above results 
demonstrated an effect of MBF on the ER, we here investigated whether MBF might affect LDs 
in cancer cells. 
Initially, the MBF effect on LDs was investigated using oil red O stain in HCC-1806 and 
CFPAC-1 cells. Treating HCC-1806 with the IC50 (8 µM) resulted in a significant decrease in the 
intensity of the red-stained LDs starting as early as 3 hours after treatment. CFPAC-1 cells 
showed similar effect, but a significant reduction in LDs concentration started later than in HCC-
1806 cells, namely 12 h after MBF treatment with 6 µM. These results suggested that lipid 
droplets might indeed undergo lipolysis or lipophagy. The difference in the time course before a 
significant decrease in LDs concentration was observed may be due to the different cell types 
and might even be due to the fact that CFPAC-1 cells have a difference in ER structure. The 
CFPAC pancreatic cancer cells originate from patient that suffered from cystic fibrosis (CF), and 
contain a mutant CF gene (Schoumacher et al., 1990), which results in a more condensed ER 
around the nucleus and differences in response to Ca2+ signaling (Antigny et al., 2011). 
Usually, cancer cells maintain a high concentration of LDs by a continuous process of de 
novo lipid synthesis. The decrease of lipid droplets concentration may reflect that the cells are in 
a state of starvation (Maan et al., 2018). Therefore, the MBF effect on the LDs was proposed 
suggesting that MBF might impact the energy production in cancer cells. 
The results from the lipolysis assay showed that MBF-induced lipolysis in CFPAC-1 
cells. Treating the cells with MBF 50 µM for 12 h resulted in an 8-fold increase of glycerol 
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concentration in the medium; moreover, treating CFPAC-1 cells with MBF at the IC50 dose (6 
µM) resulted in a 20% increase in the glycerol concentration after 36 h treatment. 
Taken together, MBF caused a reduction in the LDs’ conc in HCC-1806 and CFPAC-1 
cells through inducing lipolysis. MBF has been shown to affect the glioma cells plasma 
membrane potential by depolarization and by increasing the cytosolic Na+ concentration, causing 
the loss of the Na+ concentration gradient necessary for glucose import, and leading to cells 
starvation (Niklasson et al., 2017). 
Another possible explanation for increased lipolysis may be that MBF treatment caused 
in ER stress, which increased the cellular energy demand and resulted in the cell utilizing stored 
energy in the form of LDs (Vishnu et al., 2014). 
 
5.5 Conclusion: 
MBF caused a decrease in the LDs’ concentration and induced lipolysis in two cancer 
cell lines. This effect depletes resources required for the survival of cancer cell, proliferation and 
stress resistance. Further investigations are required to determine whether the MBF effect on 
LDs is a secondary consequence of ER stress, cell starvation or whether MBF directly stimulates 
the production of lipolysis hormones, such as hormone-sensitive lipase.  
 
 
 
 
 
 
67 
6- FINAL DISCUSSION 
 
The effect of MBF on cancer cells was primarily identified on glioma cells, but the 
studies were then extended to investigate the anticancer effect of MBF on cancer cells from 
epithelium origin (e.g., ovarian and leukemia cancer cells). Interestingly, MBF showed a 
significant anticancer effect on both glioma and cancer cells from epithelium origin. Our study 
was directed towards identifying the IC50 of MBF for different cell types, verifying the 
anticancer effect of MBF, and investigating a potentially common pathway that could be targeted 
by anticancer drugs in future studies. 
Despite the differences between different cell lines used in this study, such as the CF 
gene mutation in CFPAC-1 cells that alters their ER structure-function characteristics 
(Schoumacher et al., 1990), MBF inhibited the viability of various cancer cell lines. The 
screened IC50 doses of MBF were relatively low in comparison to the FDA approved anticancer 
drug doxorubicin.  
Because MBF has been described as a TTCC blocker, the first approach was to examine 
whether the observed effects of MBF could be explained by its action on TTCC. By using Fura-2 
imaging, we demonstrated an increase in [Ca2+]i in response to MBF treatment at IC50 doses of 6-
8 µM, which was an unexpected result for inhibiting a calcium channel. The applied doses were 
around 40 times the concentration required for blocking TTCC, whereas MBF administration at a 
dose of 0.92 µM (about 5 times IC50 for TTCC) did not show changes in [Ca
2+]i. Additional 
investigations to examine whether extracellular Ca2+ could be identified as the source of [Ca2+] 
increase showed that the increase in [Ca2+]i triggered by MBF was not abolished by eliminating 
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the extracellular Ca2+ source, but was blocked by emptying the ER Ca2+ store, which identified 
the ER as the source of the MBF-induced [Ca2+]i increase. 
The fact that cells rely on mitochondria-associated ER membranes for  Ca2+ signaling 
raised the possibility that MBF might also have an effect on the mitochondria, secondary to the 
Ca2+ release from the ER (Morciano et al., 2018). Results from the TMRE assay indicated that 
MBF indeed impacted the MX and resulted in hyperpolarization followed by depolarization of 
MX, whereas, emptying the ER Ca2+ store once again blocked the hyperpolarization effect of 
MBF. Usually, MX hyperpolarization is associated with ROS overproduction and accumulation 
in the mitochondrial inner membrane (Zhang et al., 2006). Suggesting that MBF may elicit a 
unique mechanism of inducing overproduction or accumulation of ROS in mitochondria, , which 
triggered by MBF-induced Ca2+ release from the ER and blocked by emptying ER Ca2+ stores by 
Thap. 
On the other hand, MBF-induced Ca2+ release from ER stores and its impact the MX also 
suggested that MBF might induce apoptosis in cancer cells. Flow cytometric analysis of 
AnnexinV/PI stained cells after MBF treatment showed that MBF was able to induce apoptosis 
in CFPAC-1 cells, which was also dependent on MBF-induced ER Ca2+ release. 
Recent research demonstrated that cancer cells maintain a tremendous amount of lipids in 
LDs, and that the ER is the major site for LD production. However, mitochondria dysfunction 
can also regulate cellular lipolysis (Kratky et al., 2014; Maan et al., 2018). Oil red O stain 
indicated that MBF decreased the number of LDs in cancer cells, an effect that started taking 
place after 3-12 h of MBF treatment at a dose equal to the IC50. Therefore, we sought to clarify 
the fate of the disappeared LDs employing a glycerol detection assay. Indeed, glycerol 
production by CFPAC-1 cells significantly increased upon MBF treatment at a dose of 6 µM 
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after 36 h, and at 50 µM after 12 h. Preliminary results indicated that emptying the ER Ca2+ 
stores did not halt the lipolysis effect of MBF. Therefore, future studies will have to investigate 
in detail how MBF causes increased lipolysis.   
Another interesting observation was that the HCC-1806 and CFPAC-1 cells underwent 
shrinkage during Fura-2 and TMRE imaging in response to MBF, while cells treated with 
DMSO only did not show such phenomenon. One possible explanation might be the high MBF 
doses used in those assays, that were at least 6 times the concentration required for inhibiting 
voltage-gated Na+ channels and volume-activated Cl- channels and could have restrained the 
cells’ ability to maintain their volume. 
Our results suggest that the anticancer effect of MBF is likely not related to its well 
described effect of blocking TTCC. Instead, the effect of MBF was shown to mainly depend on 
releasing Ca2+ stored in the ER. Further investigations are warranted to identify the major 
pathways that contribute to mechanism of action caused by MBF. In addition, it will also be 
important to evaluate the expression of the major markers of cellular activity, division, and 
apoptosis after MBF treatment. Moreover, conducting additional detailed studies to disclose the 
effect of MBF on lipid metabolism through monitoring the effect of MBF on the expression of 
lipolytic enzymes and perilipins, and ROS production would be of great interest. In parallel, 
MBF has a unique effect on the mitochondria and LDs, despite the finding that Thap can also 
induce ER stress and Ca2+ release. Together, these findings open multiple doors for future 
research opportunities into understanding the effect of ions homeostasis in cancer cells, as well 
as lipogesis and LDs dynamics. Further opportunities in investigating the unique effect of MBF 
on ER that was shown to be different from the classical ER stressors like Thap, which can help 
to identify a common therapeutic target among various cancer cells. 
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7- FINAL CONCLUSIONS 
 
In summary, the current research study showed that MBF-induced ER Ca2+ release is 
required for the anticancer action of MBF, which challenges the present concept of explaining 
the anticancer effect of MBF solely by its known effect of blocking the TTCC. Furthermore, the 
MBF-induced Ca2+ release was also essential for inducing a hyperpolarization of the MX and for 
cancer cells apoptosis. Understanding the unique effects of MBF will lay the foundation for new 
strategies to fight the most resistant and aggressive cancers by targeting essential cell signaling 
pathways that were pathologically altered for the benefit of the cancer cell. 
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APPENDICES  
 
Appendix A 
A-1. Cell Lines and Growing Mediums: 
The cancer cell lines used in the study were grown in suitable medium (Corning®) (Table 
A-1) and were incubated in 5% CO2 incubator (Nuaire NU-4750, Thermo Scientific 800WJ- 
Model 3578) in 37 Co. All the media were provided with 10% Fetal Bovine Serum (HyClone® 
Characterized FBS, U.S. Origin, GE Healthcare Life Sciences) and 1% Penicillin-Streptomycin 
cocktail (Corning®). 
Table A-1: The cancer cell lines used in the study and the suitable medium used for 
growing each cell line. All the growing media were supplemented with 10% FBS and 1% 
Penicillin-Streptomycin cocktail. 
Table 2 The cancer cell lines used in the study and the growing medium. 
Cell Line Growing Media 
PC-3 Luc (Prostate cancer cells) MEM 
MDA-MB-231 Luc (TNBC* cells) DMEM with 4.5% glucose 
MDA-MB-468 (TNBC cells) DMEM 
MDA-MB-231 (TNBC cells) DMEM 
HCC-1806 (TNBC cells) RPMI 
DU-145 (Prostate cancer cells) DMEM 
CFPAC-1 (Pancreatic adenocarcinoma cells) RPMI 
Panc-1 (Pancreatic cancer cells) RPMI 
Panc-89 (Pancreatic cancer cells) DMEM 
 TNBC: Triple Nigative Breast Cancer cells. 
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A.2. The ECS Composition: 
The ECS was prepared for providing the cells with non-nutritious, isotonic buffer that 
was used for washing the cells after loading the TRME and Fura-2 AM dyes, and for covering 
the cells during imaging. The ECS pH and osmolarity are 7.3 and 320 mOsm/L. All the 
chemicals used in the formulation were purchased from Sigma-Aldrich®. 
 
Table A-2: The composition of the ECS: 
Table 3 The composition formula of ESC 
No. Chemical Compound Molar conc Molecular weight 
(MW) 
The weight (mg) for 
preparing 1 L of ECS 
1 Sodium chloride (NaCl) 152 58.4 8877 
2 Potassium chloride (KCl) 2.8 74.6 209 
3 HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) 
10 238.31 2380 
4 Calcium chloride * (CaCl2) 2 111 222 
5 Glucose 10 180 1800 
 For preparing Ca2+ free ECS, the CaCl2 was replaced by the molar concentration of 
EGTA (Ethylene glycol-bis [β-aminoethyl ether]-N,N,N',N'-tetraacetic acid, MW 380). 
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